OCM™ Creates a Bioactive Scaffold That Supports Faster Wound Healing
-
HCPCS Code: A2014
-
60% Wound Area Reduction in 4 Weeks
-
FDA-Cleared Drug-Device
-
Malleable Solid Matrix
-
Marine Lipid Technology
A Bioactive Revolution in Wound Healing
Comprehensive Therapy
OCM™ wound matrix is a first-of-its-kind, drug-device combination product that provides comprehensive therapy for all phases of wound healing. It reduces biofilm formation, diminishes inflammation, increases cellular proliferation, and supports tissue remodeling. OCM™ is delivered in single-use, disposable vials.
Sustainably Sourced
Formulated and manufactured in the USA from marine by-products and ocean-derived compounds, OCM™ delivers a sustainable, antibiotic-free therapy. This bioactive matrix provides a simple, outpatient solution that eliminates the need for surgical grafting or operating room costs. Our bioactive matrix provides a simple, outpatient solution that requires no surgical grafting or operating room costs.
Key Product Benefits
OCM™ wound matrix provides pharmaceutical grade time-released elements that migrate into the tunnels and crevices of the wound bed to support each stage of wound healing.
Decrease Inflammation
Increase Proliferation
Support Remodeling
Reduce Biofilm Impact
How Does OCM™ Work?
Matrix Conformance
The anhydrous matrix conforms to both regular and irregular wound beds, establishing an immediate protective barrier over the exposed tissue.
OCM™ provides immediate structural coverage
Nutrient Infusion
A specialized blend of essential omega fatty acids, peptides, and plant-derived oils and waxes supplies vital nutrients directly to the wound bed to restart the natural healing cascade.
OCM™ is a malleable solid to fit any wound shape
Structural Regeneration
A three-dimensional scaffolding framework allows the patient’s own healthy cells to migrate and multiply, actively facilitating robust tissue regeneration and remodeling.
Formulated under strict cleanroom conditions
Advanced Healing
The factors stalling the wound are overcome, successfully pushing the chronic wound out into progressive phases of healing and closure.
Formulated under strict cleanroom conditions
How to order
Explore the available OCM™ product configurations and UDI details below:
Packaging: Pouch (contains single dose package & IFU)
Packaging: 4-pk carton (contains 4 pouches)
Packaging: 10-pk carton (contains 10 pouches)
Clinical Case Studies.
Click any study to view patient history, treatments, and progressive wound closure images.
Diabetic Foot Ulcer with Charcot Deformity
Wound history & prior therapies:
- 4 months non-healing. Collagen powder & off-loading boot
Omeza:
- Closed in 9 weeks
Venous Leg Ulcer
Wound history & prior therapies:
- 7 months non-healing. Silver alginate & amnion products
Omeza:
- Closed in 5 weeks
Tunneling Abdominal Wound
Wound history & prior therapies:
- Over 2 years old. Standard of care in skilled nursing facility
Omeza:
- Closed in 7 weeks
Venous Leg Ulcer
Wound history & prior therapies:
- 5 months non-healing. Compression, unna boots, fish skin graft
Omeza:
- Closed in 11 weeks
Testimonials
Why OCM™?
Governing our sustainable marine sourcing, documented healing outcomes, flexible application, and standard reimbursement codes.
Sustainably Sourced
Omeza transforms marine by-products into sustainable, antibiotic-free therapies—providing a simple outpatient solution with no surgical or operating room costs.
Documented Outcomes
Validated by real-world clinical case data demonstrating a 60% reduction in wound size in 4 weeks.
Anatomical Adaptability
Formulated to naturally flow into deep or tunneling spaces, seamlessly conforming to irregular wound beds and maintaining direct tissue contact where sheet matrices cannot reach.
Commercial Access
Streamlined administrative pathways featuring active CMS billing code A2014 and direct national supply access via the Veterans Affairs Federal Supply Schedule (FSS).
Research & Publications
Browse our range of peer-reviewed publications.
| January 2024 |
A Novel Comprehensive Therapeutic Approach to the Challenges of Chronic Wounds: A Brief Review and Clinical Experience Report. Bettle, Bell & Bakewell (2024). |
View Hide |
|
Bettle-Jan-2024-Advances in Therapy
PDF PREVIEW
|
||
| September 2024 |
The use of a multimodal wound matrix to treat a variety of hard-to-heal wounds: a case series surveillance. Swain et al. (2024). |
View Hide |
|
Swain-Cole-Sept 2024-Journal of Wound Care
PDF PREVIEW
|
||
| October 2024 |
A novel approach for the treatment of diabetic foot ulcers using a multimodal wound matrix: a clinical study. Simman et al. (2024). |
View Hide |
|
Simman-Oct-2024-Journal of Wound Care
PDF PREVIEW
|
||
| October 2024 |
Omega Fatty Acid-Based Therapy for Healing of Recalcitrant Wounds in Patients with Complex Comorbidities. Reinkruat et al. (2024). |
View Hide |
|
Reinkraut-Oct-2024-Advances in Skin and Wound Care
PDF PREVIEW
|
||
| October 2024 |
Antimicrobial effects of a multimodal wound matrix against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa in an in vitro and an in vivo porcine wound model. Gil et al. (2024). |
View Hide |
|
Gil-Online-Oct-2024-International Wound Journal
PDF PREVIEW
|
||
Request a Conversation with a Rep
Contact us today to request a representative and introduce OCM™ to your
wound care protocols.